| Autor: |
Spoors, John, Croft, Eleanor, Walker, Andrew |
| Zdroj: |
British Journal of Healthcare Management; 2017, Vol. 23 Issue 4, p158-166, 9p |
| Abstrakt: |
Regenerative medicine is an emerging and pressing topic which represents an enigma for healthcare decision-makers around the globe. The 'once and done' concept is attractive not only to patients and clinicians, but also to payers in areas where the therapeutic costs are high. However, regenerative medicine has had many safety challenges. Payers are therefore not only sceptical about the claimed length of benefit of treatment, but also about the various potential safety risks associated with such procedures. To payers, the reality is that gene therapy is another healthcare intervention with a different--albeit innovative--mechanism of action. Experience with early gene therapies is likely to shape the pricing and reimbursement structure for future gene therapies; and amendments may need to be made to traditional pricing and reimbursement methodology. The upfront payment model is unlikely to be affordable for most healthcare systems and therefore manufacturers should put forward innovative pricing models. Gene therapy offers the potential for a 'tectonic shift' in clinical care, but the widespread adoption is not without friction. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
